InspireMD Reports Outstanding 30-Day Results from CGUARDIANS II Trial of CGuard Prime 80 cm Stent for TCAR Procedures
Key Points from the Report
- InspireMD (Nasdaq: NSPR) announced exceptional 30-day results from its pivotal CGUARDIANS II clinical trial, evaluating the CGuard Prime 80 cm carotid stent in Transcarotid Artery Revascularization (TCAR) procedures.
- The company’s Premarket Approval (PMA) supplement for the device is currently under review by the FDA, with potential approval anticipated in the second half of 2026.
- Approval could allow InspireMD to expand its addressable market to include TCAR procedures, in addition to traditional Carotid Artery Stenting (CAS).
Detailed Clinical Results
- 100% acute device success rate: All 50 patients treated across 11 trial sites achieved successful device implantation.
- Zero major adverse events: No deaths, strokes, or myocardial infarctions were reported within the crucial 30-day period.
- No stent thrombosis: There were no reports of stent thrombosis during the 30-day follow-up.
- Complete stent patency: All evaluable subjects demonstrated full stent patency at the 30-day mark.
Expert Commentary
Dr. Patrick J. Geraghty, co-lead investigator and professor of surgery and radiology at Washington University School of Medicine, stated,
“The 30-day results observed in the CGUARDIANS II trial suggest that the CGuard Prime 80 cm stent may deliver exceptional safety and efficacy when used with a TCAR approach. Notably, the 100% acute device success rate with zero major adverse events has the potential to make CGuard Prime the gold standard implant for high-risk patients undergoing TCAR procedures. I look forward to incorporating it into my own practice, if approved.”
Management Insights and Strategic Implications
InspireMD CEO Marvin Slosman highlighted the significance of these results for the company’s strategic expansion, noting that the positive data supports their ambition to enter the large and growing U.S. TCAR market, which sees over 35,000 procedures annually.
He also referenced the recently initiated CGUARDIANS III clinical trial of the company’s proprietary SwitchGuard neuroprotection system, which, if successful and approved, could allow InspireMD to offer a comprehensive TCAR toolkit.
Regulatory Status and Market Opportunity
- The CGuard Prime Carotid Stent System 80 cm remains an investigational device in the U.S. and is not yet approved for commercial sale.
- InspireMD has submitted a PMA Supplement to the FDA, currently under review, with potential approval expected in the second half of 2026.
- If approved, this would mark a significant milestone, potentially accelerating adoption and fueling revenue growth as the company expands beyond the CAS market into TCAR procedures.
Risks and Shareholder Considerations
- Potential Price Sensitivity: FDA approval and subsequent commercialization of the CGuard Prime 80 cm stent for TCAR could be a major share price catalyst, given the size of the U.S. market and the strong clinical data supporting the device.
- Uncertainties Remain: The company cautions that forward-looking statements are subject to risks, including but not limited to:
- Regulatory delays or failure to obtain approval
- Company’s history of recurring losses and negative cash flows
- Need for additional capital, which could be dilutive
- Uncertainty over market adoption and reimbursement
- Potential manufacturing challenges and competitive pressures
- Risks associated with conducting business in multiple foreign jurisdictions, including geopolitical risks (notably in Israel)
- Shareholder Value: While the 30-day results are highly encouraging and could drive significant value if followed by regulatory and commercial successes, investors should remain alert to both upside and downside risks outlined by the company.
About InspireMD
InspireMD aims to set the industry standard in carotid stenting with its proprietary MicroNet™ mesh technology, seeking to deliver not only strong short-term outcomes but also long-term durability and stroke prevention. The company’s shares trade on Nasdaq under the ticker NSPR.
Investor Contacts
Jeff Warren
LifeSci Advisors
Email: [email protected]
Email: [email protected]
Disclaimer: This article contains information based on InspireMD’s press release and related filings. Forward-looking statements are subject to various risks and uncertainties, and actual results may differ materially. Investors should review InspireMD’s filings with the SEC, including the latest Form 10-K and 10-Q, for a full discussion of risks. This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities.
